Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
Evaluation of the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine 580299 When Administered in Healthy Females Aged 9 - 25 Years Using an Alternative Schedule and an Alternative Dosing as Compared to the Standard Schedule and Dosing
Sponsor: GlaxoSmithKline
Listed as NCT00541970, this PHASE1 trial focuses on Infections, Papillomavirus and remains completed. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Edmonton, Canada , Flensburg, Germany , Frankfurt am Main, Germany , Hamburg, Germany , Hanover, Germany , Karlsruhe, Germany , Kehl, Germany , Langley, Canada , Leipzig, Germany and 11 more locations